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The objective of this study was to compare active drug concentrations in the
plasma vs. different effector compartments including interstitial fluid (ISF)
and pulmonary epithelial lining fluid (PELF) of healthy preruminating
(3-week-old) and ruminating (6-month-old) calves. Eight calves in each age
group were given a single subcutaneous (s.c.) dose (8 mg/kg) of danofloxacin. Plasma, ISF, and bronchoalveolar lavage (BAL) fluid were collected over
96 h and analyzed by high-pressure liquid chromatography. PELF concentrations were calculated by a urea dilution assay of the BAL fluids. Plasma
protein binding was measured using a microcentrifugation system. For most
preruminant and ruminant calves, the concentration–time profile of the central compartment was best described by a two-compartment open body
model. For some calves, a third compartment was also observed. The time to
maximum concentration in the plasma was longer in preruminating calves
(3.1 h) vs. ruminating calves (1.4 h). Clearance (CL/F) was 385.15 and
535.11 mL/h/kg in preruminant and ruminant calves, respectively. Ruminant calves maintained higher ISF/plasma concentration ratios throughout
the study period compared to that observed in preruminant calves. Potential
reasons for age-related differences in plasma concentration–time profiles and
partitioning of the drug to lungs and ISF as a function of age are explored.
(Paper received 20 December 2015; accepted for publication 25 June 2016)
Dr Geof Smith, DVM, PhD, Department of Population Health and Pathobiology,
North Carolina State University, 1060 William Moore Drive, Raleigh, NC 27607,
USA. E-mail: Geoffrey_Smith@ncsu.edu

INTRODUCTION
Danofloxacin is a synthetic fluoroquinolone antibiotic licensed
for use in cattle in the United States for the treatment of
bovine respiratory disease (BRD) associated with Mannheimia
haemolytica and Pasteurella multocida. It exerts efficacy against
gram-negative and gram-positive bacteria by inhibiting bacterial DNA gyrase and topoisomerase, thereby blocking DNA
replication and effectively killing the bacteria (Drlica, 2012).
Extra-label drug use of antibiotics in food producing species
has led to concerns over an increase in the selection of resistant microbial strains, with the potential for horizontal gene
transfer and for the spread of resistant strains to other animal
and human pathogens (Martinez et al., 2014). In situations
when extra-label use is a necessity, it is essential that the prescribing practitioner select a drug that is appropriate for the
targeted pathogen, the administered dose is safe, and the
selected dosage regimen is consistent with achieving a systemic
© 2016 John Wiley & Sons Ltd

drug exposure profile that is consistent with efficacy. Integral
to defining an appropriate dosage regimen is an understanding
of the pharmacokinetics (PK) of that drug in the targeted
patient population and tissue compartments.
Danofloxacin is approved for use in ruminating calves but
does not currently have an approval for veal or preruminating
calves. While one may consider defining the dose in younger
calves simply by adjustments based on body weight, such dose
adjustments fail to recognize potential age-associated differences in drug PK. Therefore, the PK of danofloxacin in preruminant and ruminating calves needed to be examined.
Several reports have described the age-associated bovine PK
for a variety of drugs. Considering the findings associated with
sulfamethazine (Nouws et al., 1986), phenylbutazone (Volner
et al., 1990), ceftiofur sodium (Brown et al., 1996), and
meloxicam (Mosher et al., 2012), there appears to be a trend
toward a lower total systemic clearance (CL) and larger volumes of distribution at steady-state (Vss) in neonatal calves as
179
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compared to adults (approximately 6 months of age). However,
these relationships may not be universal as the Vss of the fluoroquinolone enrofloxacin was suggested to be smaller in 1-dayold calves as compared to one–week-old calves (Kaartinen
et al., 1997).
Additional considerations of pharmacodynamics (PD) and
disease progression need to be factored into dose evaluation for
neonatal calves. As the immune system of these calves is not
fully developed, it is preferable to use drugs with bactericidal
activity. This is one of the reasons why fluoroquinolones such
as danofloxacin are particularly attractive as they are known
to exert concentration-dependent action (Lees & Shojaee
Aliabadi, 2002). Typically, fluoroquinolone efficacy has been
linked to the extent of exposure over a 24-h period (area under
the curve, AUC0–24 h) at steady-state relative the minimum
inhibitory concentration (MIC) of the targeted pathogen (AUC/
MIC) and to the ratio of peak plasma drug concentrations
(Cmax) to the minimum inhibitory concentration (Cmax/MIC)
(Andes & Craig, 2002). Consistent with this pharmacokinetic/
pharmacodynamic (PK/PD) relationship, danofloxacin has been
shown to achieve high concentrations in lung tissues, with
rapid penetration into the pulmonary fluids of calves with respiratory disease (Terhune et al., 2005). However, the precise
PK/PD target necessary to achieve the desired clinical outcome
may not be identical for ruminating calves vs. preruminant
calves. Potential reasons for such age-related differences
include a dissimilarity in the partitioning of drug from the
blood to the infection site or the possible need to achieve a
greater microbicidal activity in the presence of the yet immature immune system (i.e., greater reliance on the drug vs. the
host response).
The objective of this study was to compare the drug concentrations (free and total) in the plasma vs. concentrations in the
ISF and PELF of healthy preruminating (3-week-old) and ruminating (6-month-old) calves. It is important to acknowledge
that the extra-label use of fluoroquinolones in major food producing species is prohibited by law. However, it was selected
for use in this study because it is approved for use in ruminating calves and has well-defined pharmacokinetic/pharmacodynamic (PK/PD) characteristics, and the importance of the use
of peak concentration and extent of drug exposure for determination of its antimicrobial effects needed to be examined. By
providing more data on the effect of age on PK parameters in
preruminant calves, these results could provide the scientific
foundation upon which to base assessments of potential future
applications for the use of antimicrobial compounds for use in
neonatal calves.
MATERIALS AND METHODS
Animals
This study was approved by the North Carolina State University Institutional Animal Care and Use Committee. Weaned
and unweaned male Holstein calves were bought from the
North Carolina State University Dairy herd. Eight unweaned

Holstein calves, 2–3 weeks of age, weighing between 41 and
53 kg were classified as preruminants. These calves were
housed in individual hutches at the University dairy, were fed
commercial milk replacer twice a day, and had free access to
water and calf starter ration ad libitum throughout the study.
Eight weaned calves, 6 months of age and weighing between
151 and 214 kg at time of study, were classified as ruminating
calves. The calves were group housed indoors on a concrete
floor bedded with wood shavings. Ruminant calves were maintained on grass hay and water ad libitum and were supplemented with grain. None of the calves had any previous
history of disease or antibiotic administration and had normal
physical examinations prior to start of the study. The extralabel use of fluoroquinolones is expressly prohibited in food
producing animals in the United States, and these calves were
not allowed to enter to human food supply at the completion
of the study.
Drug administration and blood collection
All calves were weighed on a digital scale on the morning of
the study commencement for determination of the administered dose. Approximately 24 h prior to start of the study,
calves were restrained for intravenous catheter placement. The
area where the catheter was to be placed was clipped and
cleaned with alternating scrubs of chlorhexidine and isopropyl
alcohol. Using sterile technique, a 14 G 9 3.25 mm catheter
(AngiocathTM, BD, Franklin Lakes, NJ, USA) was inserted into
the right jugular vein with an extension set and sutured to the
skin using a 2-0 monofilament suture. Catheters were flushed
three times a day using 6 mL of 10 units/mL of heparin saline.
A single s.c. injection of danofloxacin (8 mg/kg) (AdvocinTM;
Zoetis, Florham Park, NJ, USA) was administered to each calf
in the neck per label instructions. Blood samples were taken
from the jugular vein and were transferred to lithium heparinized tubes at 0 (pretreatment), 0.25, 0.5, 1, 2, 4, 8, 12,
24, 48, 72, and 96 h postadministration of danofloxacin.
These samples were stored on ice until centrifugation at
approximately 3500 g for 20 min to collect plasma. The
plasma samples were stored at 80 °C until analysis.
Interstitial fluid collection
All calves were implanted with s.c. ultrafiltration interstitial
fluid (ISF) probes on the side of the neck opposite site of s.c.
injection (BASI Inc, West Lafayette, IN, USA). Each probe contained three semipermeable loops connected to a nonpermeable
tube that extended outside the animal and attached to a 3 mL
no additive plastic vacutainer tube. This tube provided negative
pressure for fluid collection through small pores in the probe
membranes. These pores allowed for the movement of water,
electrolytes,
and
low
molecular
weight
molecules
(<30 000 Da) to pass into collection tube. This pore size
excludes large molecules such as proteins, protein bound
drugs, and cells. Probes were placed with calves under sedation
with xylazine [Rompunâ Injectable, Shawnee Mission, KS, USA
© 2016 John Wiley & Sons Ltd
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(20 mg/mL); Bayer Animal Health Division] at a dose of 0.05–
0.1 mg/kg in the cervical neck muscles. Probes were placed
24 h before the start of the trial to allow them adequate time
to equilibrate. One probe was inserted into each calf subcutaneously in the area cranial to the scapula. All probes were
placed through a small stab incision using an introducer needle provided by the company. The ISF was collected at 0 (pretreatment), 2, 4, 8, 10, 12, 24, 48, 72, and 96 h after s.c.
administration of danofloxacin. As each ISF sample represents
fluid collection over a certain amount of time (i.e., not instantaneous sample), a lag time was calculated based on the length
of the tube and fluid collected over time for each sample. The
fluid collected was frozen at 80 °C until analysis.
Lung fluid collection
To determine drug concentrations in PELF, a bronchoalveolar
lavage (BAL) was performed using a method described previously (Poulsen & McGuirk, 2009). Briefly, BALs were performed in all preweaned calves using a sterilized, flexible 10
French 9 36 inch catheter with a 3-cc balloon cuff and in
ruminating calves, a 24 French 9 59 inch catheter was used
(Mila International, Inc. Medical Instrumentation for Animals,
Florence KY). At each time point, the calf was restrained and
the head and neck of the calf were extended to facilitate passage of the sterile BAL catheter. The BAL catheter was introduced into the ventral meatus of the nose through which it
was advanced down the trachea until it was wedged in a terminal bronchus. Repeated coughing was used as an indicator
of appropriate placement. In the wedged position, the balloon
cuff was inflated to create a seal and the catheter was held
firmly in place while the guide wire was removed. At each
time point, 100 mL of sterile saline was infused into the lungs.
Immediately after the infusion, negative pressure was applied
to aspirate fluid. The volume of fluid that was retrieved ranged
from 0 to 55 mL of clear to mildly turbid foamy fluid. The fluid
sample was placed into a sterile collection tube, the total
amount recorded and placed on ice until centrifugation. The
BAL samples were centrifuged at 300 g for 10 min, and supernatant fluid was separated from cell pellet and frozen at
80 °C until analysis.
Drug analysis
Plasma and BAL fluid were analyzed by high-performance
liquid chromatography (HPLC) with fluorescence detection following solid-phase extraction (SPE). The ISF was injected
directly onto the HPLC. Danofloxacin was extracted from
plasma and BAL supernatant using a method described previously by Davis et al. (2007). Briefly, a 3 mL/60 mg HLB cartridge (Waters Corporation, MA) was conditioned and
equilibrated with 2 mL of methanol followed by 2 mL of water.
A 500 lL of plasma sample was added to cartridge followed by
a wash step using 2 mL of 95:5 water:methanol. The drug
was then eluted into glass tubes with 1 mL of methanol
followed by another 1 mL of methanol. The eluted sample was
© 2016 John Wiley & Sons Ltd

evaporated to dryness under nitrogen at 40 °C and reconstituted in 500 lL of mobile phase [water:methanol with 0.1%
triflouroacetic acid (85:15, v:v)] for plasma and 250 lL for
BAL samples for HPLC analysis.
The extracted plasma and BAL samples were analyzed using
a Waters XBridge C18 3.5 lm (4.6 9 100 mm) HPLC column
(Waters Corporation, MA) at 800 lL/min with an injection
volume of 25 lL. Danofloxacin was detected using fluorescence
(W2475) at an excitation wave length of 280 nm and an
emission wave length of 400 nm. Validation standards were
prepared over a linear range for each matrix (plasma, ISF,
sodium chloride 0.9%, mobile phase) and were used to construct calibration curves. These standards were validated over
the range 0.001–5.0 lg/mL in fortified (spiked) blank plasma,
BAL, and ISF with danofloxacin (reference drug standard was
provided by Zoetis) to validate the HPLC analysis. Over the validated range, the percent coefficient of variation (%CV) for
inter- and intraday averaged 10.7% with an average
recovery of 95.9%. The limit of quantification (LOQ) was 5 and
10 ng/mL, and the limit of detection (LOD) was 1 and 5 ng/mL
for plasma and BAL and ISF, respectively.
Danofloxacin Concentrations in PELF
Estimation of the amount of PELF sampled by BAL fluid was
performed using the urea dilution method as described previously in cattle (Giguere et al., 2011). Urea nitrogen concentrations in serum (UreaSERUM) and in BAL fluid (UreaBAL) were
determined by use of a urea test kit (Urea test kit; Sigma
Chemical, St Louis, MO, USA) and the absorbance values measured by use of a spectrophotometer. The volume of PELF
(VPELF) in BAL fluid was derived from the following equation:

VPELF ¼ VBAL 

UreaBAL
UreaSERUM



in which VBAL is the volume of recovered BAL fluid. The concentration of danofloxacin in PELF (DANOPELF) was derived
from the following relationship:

DANOPELF ¼ DANOBAL 

VBAL
VPELF



in which DANOBAL represented the measured concentration of
danofloxacin in BAL fluid.
Plasma protein binding
Pooled plasma was collected from five healthy calves that have
not received danofloxacin. Plasma aliquot of each age of calf
was spiked with danofloxacin, generating samples in triplicate
with concentrations of 0.01, 0.1, 1.0, and 10.0 lg/mL (Davis
et al., 2007). All samples were allowed to stand at room temperature for 30 min. A 1 mL sample of each standard was
added to the microcentrifugation device and was centrifuged at
4000 g for 10 min. The ultrafiltrate was analyzed using HPLC
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without extraction to determine unbound concentration and
protein binding of danofloxacin was then determined. Nonspecific binding of danofloxacin was determined to be minimal
in the microcentrifugation device and filter.

All PK parameters were reported as a mean  SD. As the t½
was estimated as 0.693/mean kz, the t½ values are reported as
harmonic mean  standard deviation (SD). The SD was estimated using the Delta method1 where:

Pharmacokinetic analysis
Unless otherwise indicated, all PK parameter values are
expressed relative to the unbound danofloxacin concentrations
taking into account the nonlinearity in protein binding as a
function of drug concentrations.
Plasma concentrations of danofloxacin were analyzed using
a computer software program (Phoenixâ WinNonlin/NLME,
Version 1.3 Certara, USA Inc. Princeton, NJ, USA). Nonlinear
mixed-effects modeling of danofloxacin concentrations was performed. The selected model was parameterized by clearance
and estimated volume of distribution and absorption rate constant. Model selection was based on goodness-of-fit plots,
statistical significance between models using lowest Akaike
information criteria (AIC) values obtained in Phoenixâ
software, and coefficient of variation (CV%) of the parameter
estimates. An examination of covariates was performed to
determine whether there were any factors that may explain
the variability in Cl/F, V/F, and/or Ka. Covariates investigated
included age, weight, and physiological status (preruminant vs.
ruminant). No covariates were found to significantly improve
model predictions for any parameter for danofloxacin.
A Student’s t-test from compartmental values for age differences in the two groups of calves was performed to confirm
the results obtained from NLME.
Compartmental modeling was performed to determine PK
parameters in each age group. To select between a one-, two-,
or three-compartment open body model, the AIC and the highest R2 values were evaluated. A two-compartment model was
determined to provide the best fit and therefore was the model
used to describe the danofloxacin concentration–time curve for
each calf. Parameter estimates were obtained by minimizing
the sums of the weighted deviations using a weighting factor
of 1/Yi2, where Yi is the observed plasma concentration at
time i. For the selected model, R2 values ranged from 0.81 to
0.99 for preruminant calves and from 0.87 to 0.98 for ruminant calves.
Noncompartmental analysis (NCA) was also performed to
generate estimates of the area under the curve (AUC), maximum plasma concentrations (Cmax), time to Cmax (Tmax)
(plasma and tissue fluid), and the terminal elimination half-life
(t1/2) (plasma). The AUC was estimated from time 0 to the last
measured concentration (as defined by the LOQ) using the loglinear trapezoidal method. Values of t½ were generated using
0.693/kz where kz is the slope of the log-linear portion of the
terminal depletion phase (terminal portion of the curve out to
96 h for preruminant calves and 72 h for ruminant calves.
Slopes were also estimated from Tmax to h 24 postdose to
explore the potential difference for bias in the half-life estimate
due to the slower input rate preruminating vs. ruminating
calves.

SD ¼ HM2 

vﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
uP
un
u ðHi  MHÞ2
ti¼1
n1

And where MH is the mean of the harmonic values (MH) for
P1
Xi

n
Hi is the harmonic value (kz) and HM is the harmonic mean
being report (t1/2).
ISF/plasma concentration ratios at each time point
were determined for each calf using the concentration of ISF
(unbound drug) to the total (bound and unbound) and
unbound danofloxacin plasma concentration. Statistical analyses were performed on the mean PK parameters of preruminant vs. ruminant calves using SigmaPlot (Systat Software,
Inc, San Jose, CA, USA); P-values of ≤0.05 were considered
statistically significant. The normality assumption was tested
for each variable set with the Shapiro–Wilk W-test, which is
the preferred method for testing the normality of data when
the sample size is small (Ghasemi & Zahediasl, 2012). NLME
modeling of the PELF data was unsuccessful as the data were
sparse.
Due to missing values and the sparse nature of the dataset,
PELF was evaluated using a noncompartmental analysis from
the perspective of concentrations as a function of sampling
times and the corresponding averages of those concentrations
at each time point for the ruminant and preruminant calves.
NLME modeling of the PELF data was unsuccessful as the data
were sparse.

RESULTS
There were no adverse reactions noted from placement of
ultrafiltration devices, catheters, procedures, or from the danofloxacin administration. Plasma was obtained at each time
point. The 96-h sample for ruminant calves was mislabeled
and could not be matched with an individual calf and was
excluded from analysis. Therefore, ruminant calves profiles
were truncated to 72 h postdose. Over some sampling intervals, fluid was not collected into the ISF probe or the probes
were pulled out by the calves. Therefore, ISF data are missing

1

Feiveson AH (2005). What is the delta method and how is it used to
estimate the standard error of a transformed parameter?: Explanation
of the delta method, http://www.stata.com/support/faqs/statistics/deltamethod/
© 2016 John Wiley & Sons Ltd
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at these time points. There was no significant binding of danofloxacin to the ultrafiltration probe.
Several challenges were encountered during efforts to capture the BAL fluid. Irrespective of age, BAL fluid volumes
collected ranged from 0 to 55 mL. At the 2-h sample for preruminant calves, the lavage yielded no lung fluid for three of the
calves. Greater success was achieved at the 12- and
24-h time points where fluid could not be aspirated from only
one preruminant calf each of these time points. The variability
of fluid return with the BAL procedure in the preruminant
calves could be attributed to anatomical differences and the
corresponding difficulties in achieving proper placement of the
catheter in the terminal bronchus.

Table 1. Plasma pharmacokinetic parameters in preruminating vs.
ruminating calves
Preruminating calves
Parameter
AUC0–96 (h*ug ⁄ mL)
Cl ⁄ F (mL ⁄ h ⁄ kg)
Cmax (ug ⁄ mL)
t½ (h)
Tmax (h)
Vz ⁄ F (mL ⁄ kg)

Ruminating calves

Mean

SD

Mean

SD

23.23
385.15
1.79
20.36
3.13*
4125.01

10.07
132.15
0.43
2.46
1.25
3842.5

15.17
535.11
2.12
15.31
1.44*
2693.8

1.83
66.83
0.53
4.97
1.11
1709.3

Mean pharmacokinetic parameters from two-compartment model after
single S.C. injection of 8 mg/kg danofloxacin in 3-week-old vs. 6month-old calves. Half-life parameter is reported as harmonic mean.
*Indicates significantly different by t-test (P < 0.05).

Plasma
Although drug samples at the 96 h could not be included in
the analysis for the ruminating calves, the use of the compartmental analysis enabled an analysis of values to time infinity
in all subjects. To insure that assessments of CL/F and Vd/F
are not biased by the loss of the area defined by the 72- to
96-h trapezoid, these estimates could not be reliably compared
on the basis of data generated by the NCA, but were extrapolated out to 96 h for both groups of calves in the compartmental analysis.
Age-associated differences were observed in several PK
parameters. The AUC and Tmax values tended to be greater in
the preruminant as compared to ruminating calves (Table 1).
Using the compartmental analysis, K01 (absorption rate constant) values tended to be lower in preruminants vs. ruminants
(Tables 1 and 2). Despite the observed differences in mean values as a function of age, the AUC0–96 was not statistically significant between the two groups, which likely reflect a high
degree of variability and the limited number of study subjects
per age group. The elimination rate constant (K10) tended to
be smaller in the preruminants (slower elimination). The rate
of drug distribution from the peripheral compartment back into
plasma (K21) values tended to be smaller (slower partitioning
back into the plasma) in the ruminating vs. preruminating
calves. As discussed later, these findings may be useful in
explaining the observed relationship between ISF/plasma concentrations in ruminants vs. preruminants. Compartmental
parameter rate estimates in the individual ruminant and preruminant calves are depicted in Appendix (Figure S2).
After s.c. administration, the maximum unbound danofloxacin concentration in plasma Cmax values, as generated via our
compartmental analysis, achieved a value of 1.79 lg/mL for
preruminant and 2.12 lg/mL in ruminant calves. The corresponding mean Tmax values were 3.125 and 1.44 h, respectively. The mean terminal elimination t1/2 was estimated as
20.36 h for preruminant calves and 15.31 h for ruminant
calves (Table 1). These differences were not statistically significant. To ascertain whether this difference may have been
biased by drug input rates, slopes were also estimated from
Tmax to 24 h. In this case, the profile depletion rates were similar in preruminating and ruminating calves, with
© 2016 John Wiley & Sons Ltd

Table 2. K01 (absorption rate constant) for preruminant and ruminant calves from compartmental analysis

Calf no.
1
2
3
4
5
6
7
8

Preruminant
(1/h)

Ruminant
(1/h)

0.73
0.52
0.90
0.91
2.2
0.81
0.69
0.89

1.1
19.5
2.8
1.5
24.3
1.5
24.5
10.8

Table 3. Noncompartmental analysis to determine the terminal halflife after injection of 8 mg/kg danofloxacin in 3-week-old vs. 6-monthold calves. Reported half-life was calculated using the equation 0.693/
kz value for the first distribution phase after Cmax is reached for each
group of calves

Calf no.
1
2
3
4
5
6
7
8

Preruminant
(4–24 h)

Ruminant
(1–24 h)

7.43
10.16
7.07
6.02
5.29
4.23
5.66
4.64

5.44
4.62
4.75
4.64
4.00
4.45
4.08
4.38

corresponding rather than the terminal elimination phase, the
t½ estimates ranging from 4.23 to 10.16 h in the preruminant
calves and 4.0 to 5.44 h in the ruminant calves (Table 3).
These values were substantially less than the slopes observed
in the terminal depletion phase.
A nonlinear plasma protein binding was noted, with protein
binding decreasing as concentration increased, ranging from
67 to 17% bound as danofloxacin concentrations varied from
0.01 to 10 lg/mL (Table 4). Importantly, at 10 lg/mL, the
preruminant binding was substantially lower than that of the
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where Bmax is the maximum amount of drug that is bound to
in the plasma (maximum binding capacity) and KD is the
equilibrium dissociation constant which reflects the equilibrium concentration at which the drug meets half-maximal
binding capacity. Bmax and KD values showed differences in
preruminant and ruminant calves. Bmax value was estimated
to be 6.09 lM (2.176 lg/mL) and 21.66 lM (7.740 lg/mL)
and KD values of 5.39 lM (1.925 lg/mL) and 24.88 lM
(8.892 lg/mL) in preruminant and ruminant calves, respectively. The unbound fraction was calculated using the free
concentration, Bmax and KD values using the formula previously described (Toutain & Bousquet-Melou, 2002). The
unbound fraction was not significantly different between the
two groups (Table 4).
Interstitial fluid data
Using an in vivo ultrafiltration technique to collect ISF in
repeated samples allowed for the monitoring of unbound drug
disposition over time and was less invasive than tissue biopsies.
Although some samples were missed due to occlusion of the
probe or the calf movement around the hutches, these devices
were well tolerated and collected between 0.05 lL and >2 mL
of fluid for drug analysis.
The mean (SD) plasma and ISF samples from both groups
of calves are shown in Fig. 1 (n = 8 calves in each group). A
comparison of ISF and plasma (bound and unbound) concentrations is shown in Fig. 2 for each group of calves. The Tmax
for ISF fluid occurred later than in plasma irrespective of calf
age. Whether considering the ratios of ISF to total or free

Pulmonary epithelial lining fluid
Average PELF concentrations from the BAL samples were
reported in Table 5 and are seen graphically in Fig. 4. The
maximum concentration in PELF was noted to occur at 2 h
postadministration in both preruminant and ruminant calves,
with estimated PELF concentrations far exceeding the concentrations seen in plasma and ISF. Greater variability in drug
concentrations in PELF was seen in the preruminant calves as
compared to ruminating calves.

(a)
Concentration (µg/mL)

Cbound

Cfree
¼ Bmax
Cfree þ KD

plasma danofloxacin concentrations, the ISF/plasma concentration ratios tended to be higher in ruminant calves as compared
to that seen in the preruminant calves (Fig. 3).
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Preruminant calves

1

[Total plasma]
[Unbound plasma]

0.1

0.01

0.001

0
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100

Time (h)

(b)
Concentration (µg/mL)

ruminant calves. Kd and Bmax values were estimated using
the plasma protein binding data in preruminant and ruminant
calves using a graphic software (GraphPad Software, Inc, La
Jolla, CA, USA). The relationship between bound and free concentrations in plasma was best described by a saturable binding model using the following equation:
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Ruminant calves

1
[Total plasma]
[Unbound plasma]

0.1
0.01
0.001

0
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60
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100

Time (h)

Preruminant

Ruminant

Concentration
(µg/mL)

Mean

Calculated
% bound

Mean

Calculated
% bound

0.01
0.1
1.0
10.0

68.3
67.0
46.8
17.64

53
53
47
18

65.6
63.4
44.9
33.2

47
47
45
33

Percent plasma protein binding of danofloxacin spiked plasma from
preruminant (3-week-old) and ruminant (6-month-old) calves and calculated % bound using the equation from (Toutain & Bousquet-Melou,
2002). Samples were spiked in triplicate at four concentration levels
(0.01, 0.1, 1.0, and 10 µg/mL) and averaged.

(c)
Concentration (µg/mL)

Table 4. Average % Plasma protein binding and calculated % bound of
danofloxacin using microcentrifugation
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Fig. 1. Mean plasma (bound and unbound)  SD concentrations after
single S.C. injection of 8 mg/kg danofloxacin in preruminant (a) and
ruminant calves (b). (c). Average Interstitial fluid danofloxacin concentrations  SD.
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Table 5. Pulmonary epithelial lining fluid concentrations in preruminant vs. ruminant calves
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plasma]
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3.1
0.62
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3.6
0.86

3.6
0.36
0.44

1.7
0.06
0.36

Mean 士 SD in PELF determined from bronchoalveolar lavage after single. S.C. injection of 8 mg/kg danofloxacin in ruminant and preruminant calves.
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Fig. 2. Mean total plasma (a) and unbound (b) and ISF concentrations
after single S.C. injection of 8 mg/kg danofloxacin in preruminant
and ruminant calves.

Fig. 4. Average danofloxacin concentrations in ruminant calves PELF.
Dashed line represents the average PELF concentrations from ruminant
calves. Two data points were omitted from analysis from calf 7.

of a larger project to compare the PK of different antimicrobials in both healthy and diseased calves of varying ages to
examine what differences may be present related to age and
physiologic development.
Half-life comparisons

Fig. 3. ISF/Unbound plasma concentration ratios in ruminant and preruminant calves. Each point is a calculated geometric mean at each
time point.

DISCUSSION
Danofloxacin is approved in the United States for the treatment of bovine respiratory disease in calves. It is not
approved for use in cattle intended for dairy production or for
calves to be processed for veal. In the United States, extralabel use of fluoroquinolone antibiotics is prohibited by law
(Davis et al., 2009). Although the calves used in this study
were Holsteins, these steers were not meant for veal production. They were all ultimately shipped to a feedlot to be finished as beef. Danofloxacin was chosen in this study as part
© 2016 John Wiley & Sons Ltd

Danofloxacin is labeled to be given once s.c. at 8 mg/kg for the
treatment of bovine respiratory disease. Past studies on the PK
parameters of danofloxacin in 2- to 8-month-old calves have
reported t1/2 values ranging from 2.65 to 7.4 h when administered at 1.25 mg/kg intravenous (Friis, 1993; Giles et al.,
1991, McKellar et al., 1999; Shojaee Aliabadi & Lees, 2003).
The reported mean plasma t1/2 in this study was considerably
longer than these other reported values. Using NCA, the t1/2,
for the first distribution phase (from 4 to 24 h for preruminant
calves and 1–24 h for ruminant calves) was very similar to
those values reported in previous studies, indicating that the
observed difference between our results and those reported by
other investigators primarily reflected our ability to capture a
second depletion phase. Most of previous studies reported total
(unbound + bound) concentration, which may miss significant
changes as a function of age in clearance, volume of distribution, and other parameters. As only unbound drug is free to
move across barriers and is active to fight infections, reporting
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unbound concentrations is a more clinically significant when
determining drug concentrations at the active sites.
All calves used in this study remained clinically normal
throughout the study, but it has been noted previously that
disease status may also affect the t1/2 of danofloxacin. Apley
and Upson (1993) reported that crossbred steer calves with
acute pneumonia had a t1/2 of approximately 6.3 h (Apley
& Upson, 1993). Estimates of t1/2 can be influenced by several physiological and experimental factors, including the
experimental design (such as sampling time) and the composite effects of drug distribution and free drug clearance
(Toutain & Bousquet-Melou, 2004). The ramifications of
such differences as it pertains to unbound drug concentrations at the site of infection need to be considered from the
perspective of the etiology of any age- or disease-associated
change in drug PK.
Absorption comparisons
While there were no statistically significant differences in the
observed preruminant vs. ruminant danofloxacin Cmax values,
there was a significant difference (P < 0.006) in the time to
maximum concentration (Tmax). Preruminant calf peak concentrations were observed between 2 and 4 h in all but one calf.
In contrast, the corresponding ruminant Tmax values ranged
between 0.5 and 1 h in all but one ruminating calf. The significant difference noted between these two age groups of calves
following s.c. injection was reflected in the fitted absorption
rate constants (K01). From the NLME model, the reported K01
values were around 2.18/h. Considering some of the physiological changes that occur during the maturation of neonatal
humans (Batchelor & Marriott, 2013), the larger K01 values
observed in the older calves could be a function of such maturation-induced differences as higher body temperature, body
composition (lower tissue fluid volumes), and a greater local
tissue blood flow as compared to that of neonates (Evans et al.,
1975). With respect to the latter point, pediatric human
patients have been shown to have relatively lower density of
skeletal muscle capillaries than that in adults. This may have
also contributed to the lower bioavailability of drugs after
intramuscular and s.c. routes of administration in neonates
(Carry et al., 1986). An increase in vascular perfusion to certain muscle groups increase with age and may impact drug
absorption rates (Greenblatt, 1976).
Plasma protein binding
Initially, protein binding was thought to potentially contribute
to some of the kinetic differences observed between preruminant vs. ruminant calves. As only the unbound fraction can
reach the site of action, the distribution and availability are
greatly influenced by the degree of protein binding of certain
drugs. Frequently, the unbound fraction of many drugs is
higher in human neonates and infants as compared to that of
adults because of their lower concentration of binding proteins
(Kearns et al., 2003; Grandison Monica & Boudinot, 2000).

Coupling this difference in protein with a large extracellular
fluid volume may account for the larger drug volume of distribution occasionally observed in neonates.
In the current study, within the range of concentrations
observed in the plasma (0.01–1.0 lg/mL), only small differences in plasma protein binding were observed as a function of
age. Therefore, plasma protein binding is unlikely to have had
a significant impact on the age-associated PK differences
observed in this study. This conclusion is supported by examining the similarity in the relationship between total vs. free drug
concentration–time profiles in preruminant vs. ruminating
calves (Fig. 1). Similar estimates of danofloxacin protein binding were reported in buffalo calves (36% at concentrations
ranging from 0.0125 lg/mL to 1 lg/mL). (Sappal et al.,
2009). A strong nonlinear binding has already been reported
by Friis et al. (Friis, 1993) not only in plasma, but also in
bronchial and nasal secretions.
Although average protein binding was similar in the linear
range of 0.01–1 lg/mL, percent protein bound tended to be
higher in ruminant calves at 10 lg/mL. The origin of these
differences was not investigated; however, in human pediatric patients, a decrease in gestational age was directly proportional with a decrease in binding capacity of albumin,
but did not affect the binding affinity to albumin (Bender
et al., 2007). There was a lack of fit of the algorithm used
to estimate Bmax and KD at lower concentrations which was
noticed in the predicted and observed values for both groups
(Table 4). This could reflect that the danofloxacin binding
may be better defined by a different equation than was used.
Differences were noted between the two age groups suggests
a binding capacity and efficiency changes as a function of
age but the validity of such assumptions is the subject of
ongoing research. Although plasma protein binding of fluoroquinolones is usually associated with albumin, there is some
evidence that this group of drugs may bind to other binding
proteins, including ɑ1-acid glycoprotein (Barbato et al.,
2007). In calves, increase in ɑ1-acid glycoprotein concentrations are seen over the first 30 days of life, which could
explain differences noted in Bmax and KD values in these two
age groups (Tothova et al., 2015). When unbound concentrations tend toward the number of available binding sites,
protein binding becomes concentration dependent (i.e., saturable binding). Clinical differences in PK were not observed
in this study. In future studies, alternative algorithms for
describing the relationship between drug concentration and
free fraction should be explored.
Based upon the PR and R plasma concentrations noted in
this study, assessments of the potential impact of protein binding on danofloxacin PK should be limited to a range of 0.01–
1.0 lg/mL. Based upon the in vitro data generated within this
concentration range, there were no differences in the free fraction as a function of age. For this reason, so long as the danofloxacin blood levels remain within this concentration range,
age-associated differences in protein binding should have
negligible influence on danofloxacin clearance of distribution
kinetics.
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Clearance and volume of distribution comparisons
The CL/F values of danofloxacin did not differ significantly between
ruminant and preruminant calves. Assuming bioavailability (F)
was very similar, clearance values (578 mL/kg/h) determined in
11- to 13-week-old calves were similar to those reported in the
current study (Sarasola et al., 2002). At this concentration and
dose range, the clearance does not appear to change, implying that
a change in dose would not change PK parameters. Although significance was not seen when comparing 3-week-old vs. 6-monthold calves, maturation differences of clearance values in younger
calves (less than three weeks of age) may impact the intrinsic
clearance and elimination of danofloxacin.
In urine, unchanged danofloxacin accounted for 88–94% of
total drug, while the desmethyl metabolite accounted for the
remainder (Pfizer Inc, 1989a). At birth, both phase I (primarily
oxidation) and phase II (conjugation) metabolic enzymes in the
liver may be immature, as well as lack of functional tubular
transporters in the kidneys. Maturation of different elimination
pathways (including liver and kidney) may impact drug metabolism and clearance and may explain why the impact of age
on the reported mean half-lives vary depending on the class of
drugs studied (Reiche et al., 1980; Nouws et al., 1983). The
increase in glomerular filtration rate (GFR) in neonates during
the first few weeks of life is mainly due to an increase in renal
blood flow, which would increase the clearance values of drugs
eliminated by renal pathways as calves mature (Baroni et al.,
2008).
Statistical significance was not achieved in the age comparison of CL/F, Vd/F, or of t1/2 values. It is likely that the lack of
statistical significance was largely attributable to study size. If
the study was powered differently (contained a larger number
of study subjects), statistically significant differences in these
parameters may have been detected.
Interstitial fluid/plasma ratio comparisons
The observed PK differences in neonatal vs. mature calves led
to a question on how these age-related differences may influence the relative concentration vs. time profiles (free or total)
in the ISF or PELF vs. plasma. With respect to the ISF, this
relationship was described both by the total or free danofloxacin concentration vs. time profiles in plasma. ISF/plasma ratios
were examined before and after correcting the plasma concentrations for protein binding, taking into account the nonlinearity of plasma protein binding reported in both groups of calves
(Fig. 3). As the total plasma drug concentrations exceed the
free drug concentrations, in plasma, the ISF/plasma ratios are
greater when considering the ISF concentrations (which are
free values) to the free vs. to the total plasma drug concentrations (Fig. 3). Although the depletion-phase ISF concentrations
were consistently higher than the plasma concentrations for
both age groups, after an initial lag time, the ISF concentrations tended to more closely follow the total plasma concentration vs. time profile in preruminants than it did in ruminants
(Fig. 2).
© 2016 John Wiley & Sons Ltd

The observation that the best fit was a two-compartment
model is inconsistent with the suggested presence of a deep
compartment in some ruminant calves. Upon examining the
data, although there is a suggestion of a change in slope
(which would be consistent with a third, or deep, compartment), there were an insufficient number of time points to adequately characterize that final depletion component. However,
based upon ISF data and visual examination of the profiles, the
authors believe that a deep compartment was in fact present.
Differences were noted in the shapes of the ratios of ISF/
plasma in preruminants vs. ruminants as a function of time
(Fig. 3). For the preruminants, the ratios peaked at 24 h but
then tended to remain relatively consistent through the
remaining sampling times as compared to ruminant calves, In
contrast, the ratios continued to decline over the duration of
sampling period in ruminant calves. There are several factors
should be considered when trying to understand the observed
ISF/plasma relationships:
a) The method used for capturing the ISF reflects an averaging
of concentrations over a collection period. Accordingly,
when estimated at the time of fluid sampling, the measured
concentration will exceed the actual concentration of drug
in the ISF at any given moment in time. Thus, the use of
ultrafiltration tends to overestimate ISF concentrations at a
point in time. However, with the longer interval over which
the ISF samples were collected toward the terminal portion
of the curve, the ‘averaging’ effect would be expected to
increase and not decrease the ISF/plasma ratios over time
(i.e., a magnification of the experimental error). It is unlikely
that this confounding factor was responsible for the
observed decrease in the ISF/plasma ratios as a function of
time in ruminants.
b) The concept of rate-limiting factors needs to be considered.
In this regard, the trend toward slower Cl/F (and K10) and
faster K21 values in preruminant as compared to that in
ruminants can lead to a greater similarity in ISF vs. plasma
concentrations in preruminant vs. ruminating calves. More
explanation on calculating transfer rate differences is discussed further in the Appendix S1.
c) A potential physiological basis for this difference in shapes of
the ruminant vs. preruminant ISF/plasma ratio profiles may
be related to the higher amount of body fat in the older animals. As danofloxacin is a lipophilic drug, it could more
easily distribute into the body fat of older animals. The body
fat could then serve as a ‘deep compartment’ whose effects
would be evident primarily at the very low drug concentrations. Adipose tissue in cattle has been shown to express
a1-glycoprotein, which may bind to danofloxacin in the tissues (Rahman et al., 2015). This is consistent with the smaller K21 values seen in the ruminating vs. preruminating
calves. When this deep compartment becomes the
rate-limiting factor in the elimination of drug from the central compartment, the depletion of drug from the plasma
(CP) becomes slower than was observed at earlier time
points. Simultaneously, with regard to the ISF, with the K12
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being similar to that of the K21 in ruminating calves, the
ISF concentrations temporarily declines at a rate slightly faster than that of the blood (as was seen on the average values plotted in Fig. 1). In view of this proposed scenario, the
decrease in ISF/plasma would not be as evident in the preruminants both because of slower K10 values relative to other
intercompartmental rate constants and because of the lower
amount of body fat would limit the influence of this potential ‘deep compartment’. With these similar K12 values but
smaller K21 values in ruminating vs. preruminating calves,
one might expect that the danofloxacin Vd/F values would
have been larger in the older calves. However, similar values
were observed as a function of age (with mean values of
preruminants exceeding that of the ruminating calves). It is
likely that this apparent inconsistency is attributable to the
magnitude of variability observed across individual calves.
Potential PK/PD targets
Ultimately, one of the goals of this work is to facilitate the use
of plasma concentration vs. time profiles as a mechanism for
generating age-associated dose adjustments. However, this
assumes that preruminant and ruminating calves have identical PK/PD targets. It is now recognized that the use of targeted
plasma concentrations as the PK/PD metric for dose evaluation
is best when it is linked to the outcome of clinical trials
(Ambrose et al., 2001). However, within veterinary medicine,
practitioners often rely upon prior literature-based targets and
an assumption that the plasma concentrations in normal
healthy animals reflect the free (active) drug concentrations at
the site of infection. Therefore, as part of this study, sampling
of the PELF should relate to the concentration of free (active)
drug in lung fluids. Past methods for determining lung concentrations in many veterinary species include biopsies, bronchial
microsampling probes and bronchoalveolar lavages (BAL), and
tissue homogenate (Winther, 2012; Giguere et al., 2011;
Menge et al., 2012; Bidgood & Papich, 2005; Davis et al.,
2006, 2007; Messenger et al., 2012; Warren et al., 2014).
Tissue homogenate represents a composite of cells, plasma,
interstitial, pulmonary epithelial lining fluids, and tissue concentrations, which may falsely increase the estimates of drug
concentration at the specific sites of infection and lead to incorrect clinical drug distribution conclusions (Mouton et al.,
2008). Lung homogenate does not allow for the differentiation
between intracellular vs. extracellular drug concentrations, or
the degree of binding that may have occurred between drug
and pulmonary tissues (Gonzalez et al., 2013). However, for
many veterinary species, cost and availability for many of
these techniques limit their use in PK studies.
The PELF is secreted extracellularly in the respiratory tract
and is a potential site for bacterial colonization, making it an
ideal target for evaluating the relationship between plasma PK/
PD vs. target site exposure in pneumonia in calves and for
designing dosage regimens for therapeutic purposes in calves.
To obtain these data, a BAL technique was used to harvest
PELF. The observed higher concentrations in PELF as

compared to plasma and ISF most probably reflect methodology-associated biases in PELF danofloxacin concentrations. In
this regard, several limitations with this method have been
described in literature, including under- and/or overestimation
of drug concentrations in this matrix. The volume of PELF harvested from the BAL fluid is usually estimated using a dilution
marker such as urea. When urea is used as a dilution marker,
the dwell time of fluid infused in the airways during the BAL
procedure may represent an important source of error and
experimental variability (Baldwin et al., 1992; Dargaville et al.,
1999). Several other limitations include overestimating drug
concentrations in PELF due to potential ‘contamination’ of the
fluid from cells, the dilution factor caused by repeated infusion
of large amounts of fluid in the airway, and the problems with
using the urea correction method to adjust for this dilution.
Other studies performed in larger calves showed PELF concentration measurements are inherently highly variable and
affected by the method of collection.
Lung microdialysis method may offer a better overall determining free drug concentration in the PELF (Kiem & Schentag,
2008). Previous studies using microdialysis have correlated free
antibiotic concentrations in lungs with unbound concentration
in muscle tissue (Marchand et al., 2005) Moreover, recent evaluation of PELF concentrations of ciprofloxacin and enrofloxacin in
mature calves showed a PELF/plasma ratio of about 40% based
upon PELF values harvested via bronchial absorptive swabs
(Foster et al., 2016). Nevertheless, as any error-associated bias
attributable to our method of PELF sampling would be expected
to equally influence the data generated in all of the study animals, conclusions derived from the comparison of danofloxacin
lung concentrations of age are expected to be valid.
When comparing the mean PELF concentrations in ruminants vs. preruminants, it would appear that the concentrations tended to be markedly higher in the neonatal calves.
However, when examining the individual subject data (Fig. 4),
it is evident that such conclusions may be incorrect. The range
of values observed in the preruminating and ruminating calves
was very large, and the reliability of the means was further
compromised by missing data points, particularly in the preruminant treatment group. Therefore, the PELF values should be
considered as only a rough approximation of pulmonary drug
concentrations. Particularly in the preruminating calves where
substantial technical difficulties were encountered, it may be
necessary to identify some alternative procedure for estimating
active drug concentrations in the lung.
The measurement of the unbound danofloxacin in ISF and
PELF is ideal as most respiratory pathogens seen in calves are
extracellular bacteria. By measuring the drug concentration in
the active sites of infection, a more accurate conclusion of clinical efficacy can be determined. Many studies report the use of
specific target ratios using AUC and Cmax values to determine
the clinical efficacy (Tessman & Giguere, 2011). The problem
with extrapolating these ratios from ruminating calves to preruminant calves is that targets to achieve efficacy may vary
between the two age groups. The host immune competency as
well as bioburden at the site of action may differ between these
© 2016 John Wiley & Sons Ltd
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two groups, and more research is needed to determine age
effects on clinical efficacy, especially considering younger
calves may not have a fully mature immune system.
A limitation in the current study is relying on the use of the
statistical t-test to determine the significance. As preruminant
calves have a larger variability, there is the possibility that
there was an underlying violation of homogeneity of variances
across age groups for the parameters undergoing evaluation.
Furthermore, given the large variability, the power to detect
statistical differences was low. In this regard, a larger sample
size for each group would have helped to achieve a better
study power.

CONCLUSIONS
Trends toward differences in CL/F, rate of drug absorption,
Vd/F, and t½ were observed as a function of calf age. However, the lack of study power prohibited the detection of statistically significant differences. A deep or third compartment,
similar to previous studies, was detected and was most evident in the ruminating calves. This contributed to age-associated differences between the relationships of ISF/plasma
over time.
The ability to quantify drug concentrations out to 96-h postdose and the successful utilization of in vivo ultrafiltration and
BAL techniques provided the opportunity to obtain unique
insights into potential factors responsible for age-associated differences in danofloxacin PK in calves. Although efforts to
explain the source of these differences remain speculative, it
has identified additional questions that need to be resolved.
Specifically, if an objective is to use data derived from ruminating calves to support approvals in preruminating animals, it is
evident that further examination is needed to determine
whether there are differences in the impact of disease on drug
PK and the relationship between drug exposure vs. response.
In addition to clinical reasons for resolving these issues, the
alteration of drug PK as a function of age and disease could
impact withdrawal time considerations.
There are limited data in veterinary species addressing
pediatric-specific PK data, and these results raise several questions about the physiological changes that may impact PK in
animals of various age, as well as disease state. Further studies are warranted to compare concentrations in PELF and ISF
of diseased vs. healthy calves and the impact of these
relationships on drugs presenting with distributional
characteristics that differ from those associated with the
fluoroquinolones.
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